NR1H4 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This Target Evaluation Report for NR1H4 is generated from PatSnap Life Sciences MCP data workflows, combining Target & Disease MCP biology context with Clinical Trials MCP validation and competitive signals.
For AI teams building biomedical agents, PatSnap Life Sciences MCP Servers provide structured retrieval across target biology, disease context, clinical trials, drug evidence, IP intelligence, and other R&D intelligence sources.
107 Direct drug records from Target & Disease MCP | 73 Development records in target context | 110 Disease associations captured | 546 Clinical trial records from Clinical Trials MCP |
Explore PatSnap Life Sciences MCP Servers for AI agents
Executive View
Biology signal
NR1H4 encodes FXR, the bile acid receptor. Target & Disease MCP describes its role in bile-acid homeostasis, enterohepatic circulation, lipid and glucose homeostasis, innate immunity, intestinal barrier protection, and inflammatory cytokine repression.
Validation evidence
The target has a large hepatology and metabolic footprint: 107 drug records, 73 development records, 110 disease associations, and 546 clinical trial records. Trial examples include UDCA-related liver, renal, and metabolic contexts.
Competition and differentiation
FXR has strong rationale but clinical execution is nuanced. Differentiation depends on pruritus, lipid effects, liver endpoint strength, intestinal versus systemic activity, and whether the program improves on first-generation agonist liabilities.
IP and partnering view
IP diligence should focus on agonist chemistry, tissue bias, bile-acid pathway combinations, MASH/PBC/PSC use claims, and safety-management language.
Clinical Validation and Competitive Landscape
Clinical Trials MCP returned 546 registered trial records connected to NR1H4. The sample below is used as a directional competitive readout rather than a full regulatory review.
| Trial | Phase | Status |
|---|---|---|
| UDCA for atopic dermatitis with hyperlipidemia and fatty liver | Not Applicable | Not yet recruiting |
| Perioperative UDCA for renal protection in partial nephrectomy | Phase 2 | Recruiting |
| UDCA supplementation on liver regeneration in LDLT recipients | Not Applicable | Not yet recruiting |
R&D Strategy Recommendation
NR1H4/FXR remains attractive where the product can manage tolerability and liver-metabolic endpoints. MCP monitoring should track FXR competitors, UDCA-related trials, and hepatology positioning.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
